• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Talphera to Host First Quarter 2024 Financial Results Call and Webcast on Tuesday, May 14, 2024

    5/2/24 4:15:00 PM ET
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TLPH alert in real time by email

    SAN MATEO, Calif., May 2, 2024 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will release first quarter 2024 financial results after market close on Tuesday, May 14, 2024, then host a live webcast and conference call at 4:30 p.m. Eastern Daylight Time/1:30 p.m. Pacific Daylight Time to discuss the results and provide an update on the Company's business.

    Webcast Information

    The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.

    Conference Call Information

    Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of Canada. The conference ID is 79169.

    About Talphera, Inc.

    Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad™, is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe. This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.

    Talphera Logo (PRNewsfoto/Talphera, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-first-quarter-2024-financial-results-call-and-webcast-on-tuesday-may-14-2024-302135055.html

    SOURCE Talphera, Inc.

    Get the next $TLPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TLPH

    DatePrice TargetRatingAnalyst
    1/28/2025$4.00Buy
    Rodman & Renshaw
    More analyst ratings

    $TLPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Talphera with a new price target

      Rodman & Renshaw initiated coverage of Talphera with a rating of Buy and set a new price target of $4.00

      1/28/25 7:17:45 AM ET
      $TLPH
      Biotechnology: Pharmaceutical Preparations
      Health Care